Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
AssigneeMitomics Inc.
InventorsRyan Parr, Robert Thayer, Gabriel Dakubo, Jennifer Maki, Kerry Robinson, Andrea Maggrah, Brian Reguly, Andrew Harbottle, Mark Birch-Machin
Life of this patent
Estimating the term…
Abstract
Mitochondrial DNA deletions useful for the detection of cancers and sun exposure are provided. In particular, methods and kits for detecting mitochondrial DNA deletions for the early detection, diagnosis and progression of prostate cancer, sun exposure and non-melanoma skin cancer are provided.
Claims17
A method of detecting a deletion spanning approximately nucleotides 10744 to 14124 of the human mtDNA genome, wherein said deletion is associated with prostate cancer, in a subject having mtDNA, comprising:
- (a) providing a biological sample from the subject;
- (b) extracting mtDNA from the biological sample;
- and
- (c) detecting the presence of the deletion in the mtDNA.
A method comprising detection of an mtDNA deletion spanning approximately nucleotides 10744 to 14124 of the human mtDNA genome as a biomarker for prostate cancer.
A method for confirming or refuting a prostate cancer biopsy test from a biopsy sample, comprising:
- (a) obtaining a normal tissue from a biopsy sample;
- and
- (b) detecting the absence or presence of a human mtDNA deletion at approximately nucleotides 10744 to 14124 of the human mtDNA genome in the normal tissue.
A method for three-dimensional prostate tumour mapping, comprising:
- (a) obtaining sextant needle biopsy samples;
- (b) extracting mtDNA from the biological samples;
- and
- (c) detecting the absence or presence of a deletion spanning approximately nucleotides 10744 to 14124 of the human mtDNA genome in each of the sextant samples.
A method for diagnosing prostate cancer, comprising hybridizing nucleic acids to an array, wherein the array comprises at least one nucleic acid member, and a solid substrate, wherein the at least one nucleic acid member is associated with a human mtDNA deletion at approximately nucleotides 10744 to 14124 of the human mtDNA genome, wherein the at least one nucleic acid member has a unique position on said array and is stably associated with the solid substrate.
A method for diagnosing prostate cancer comprising using a kit, wherein the kit comprises an array comprising at least one nucleic acid member and a solid substrate, wherein the at least one nucleic acid member is associated with a human mtDNA deletion at approximately nucleotides 10744 to 14124 of the human mtDNA genome, wherein the at least one nucleic acid member has a unique position on said array and is stably associated with the solid substrate and at least one member selected from the group consisting of:
- a disposable chip, means for holding the solid support, means for extraction of mitochondrial DNA, primers, reagents and instructions.
Dependencies are inferred from the claim text.